Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M47,666Revenue $M20,314Net Margin (%)13.4Z-Score2.4
Enterprise Value $M56,880EPS $1.5Operating Margin %17.4F-Score8
P/E(ttm))17.4Cash Flow Per Share $5.9Pre-tax Margin (%)15.9Higher ROA y-yY
Price/Book2.010-y EBITDA Growth Rate %14.4Quick Ratio0.8Cash flow > EarningsY
Price/Sales2.35-y EBITDA Growth Rate %-1.5Current Ratio1.2Lower Leverage y-yY
Price/Cash Flow7.3y-y EBITDA Growth Rate %49.5ROA % (ttm)5.8Higher Current Ratio y-yY
Dividend Yield %2.1Insider Buy (3m)0ROE % (ttm)12.0Less Shares Outstanding y-yN
Payout Ratio %36.0Shares Outstanding M855ROI % (ttm)0.2Gross Margin Increase y-yY

Gurus Latest Trades with TEVA

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
TEVAJean-Marie Eveillard 2014-09-30 Add0.19%$50.94 - $55.05
($52.93)
$ 55.755%Add 710190%1,420,580
TEVAGeorge Soros 2014-09-30 Reduce-0.42%$50.94 - $55.05
($52.93)
$ 55.755%Reduce -14.32%6,231,722
TEVATom Gayner 2014-09-30 Reduce-0.36%$50.94 - $55.05
($52.93)
$ 55.755%Reduce -36.02%444,000
TEVAVanguard Health Care Fund 2014-09-30 Reduce-0.27%$50.94 - $55.05
($52.93)
$ 55.755%Reduce -26.99%5,362,100
TEVANWQ Managers 2014-09-30 Reduce-0.21%$50.94 - $55.05
($52.93)
$ 55.755%Reduce -7.62%4,698,117
TEVAMichael Price 2014-06-30 Add0.71%$48.69 - $54.06
($51.09)
$ 55.759%Add 28.73%500,000
TEVARichard Snow 2014-06-30 Add0.21%$48.69 - $54.06
($51.09)
$ 55.759%Add 6.9%1,826,799
TEVAGeorge Soros 2014-06-30 Reduce-1.59%$48.69 - $54.06
($51.09)
$ 55.759%Reduce -29.45%7,273,240
TEVAVanguard Health Care Fund 2014-06-30 Reduce-0.73%$48.69 - $54.06
($51.09)
$ 55.759%Reduce -40.54%7,344,400
TEVANWQ Managers 2014-06-30 Reduce-0.56%$48.69 - $54.06
($51.09)
$ 55.759%Reduce -19.21%5,085,717
TEVAJames Barrow 2014-06-30 Reduce-0.19%$48.69 - $54.06
($51.09)
$ 55.759%Reduce -18.5%10,868,770
TEVAKen Heebner 2014-06-30 Sold Out -0.13%$48.69 - $54.06
($51.09)
$ 55.759%Sold Out0
TEVAGeorge Soros 2014-03-31 Add0.52%$39.88 - $50.22
($45.91)
$ 55.7521%Add 10.67%10,310,041
TEVADavid Dreman 2014-03-31 Add0.15%$39.88 - $50.22
($45.91)
$ 55.7521%Add 24.43%183,323
TEVANWQ Managers 2014-03-31 Add0.14%$39.88 - $50.22
($45.91)
$ 55.7521%Add 5.04%6,294,655
TEVAKen Heebner 2014-03-31 Buy 0.13%$39.88 - $50.22
($45.91)
$ 55.7521%New holding, 95000 sh.95,000
TEVAJohn Keeley 2014-03-31 Buy 0.04%$39.88 - $50.22
($45.91)
$ 55.7521%New holding, 47435 sh.47,435
TEVARichard Snow 2014-03-31 Reduce-0.43%$39.88 - $50.22
($45.91)
$ 55.7521%Reduce -13.55%1,708,890
TEVAGeorge Soros 2013-12-31 Add1.96%$36.59 - $41.7
($39.39)
$ 55.7542%Add 158.2%9,316,000
TEVARichard Snow 2013-12-31 Add0.89%$36.59 - $41.7
($39.39)
$ 55.7542%Add 38.53%1,976,831
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

TEVA is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
TEVA Jean-Marie Eveillard 2014-09-301,420,5800.170.19+710190%
TEVA John Keeley 2014-09-3047,7100.010.05+0.58%
TEVA Ronald Muhlenkamp 2014-09-30176,8550.021.7
TEVA Michael Price 2014-09-30500,0000.063.4
TEVA David Dreman 2014-09-30157,4490.020.69-1.03%
TEVA Richard Snow 2014-09-301,796,4990.213.3-1.66%
TEVA James Barrow 2014-09-3010,370,3531.210.76-4.59%
TEVA NWQ Managers 2014-09-304,698,1170.552.7-7.62%
TEVA George Soros 2014-09-306,231,7220.732.5-14.32%
TEVA Vanguard Health Care Fund 2014-09-305,362,1000.630.74-26.99%
TEVA Tom Gayner 2014-09-30444,0000.050.67-36.02%
Premium Most recent portfolio changes are included for Premium Members only!


TEVA: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about TEVA :

    Quarterly/Annual Reports about TEVA:

      News about TEVA:

      Articles On GuruFocus.com
      Weekly 52-Week Highs Highlight: ITW, ESRX, TEVA, CHD, STI Dec 08 2014 
      Zoetis in a Growing Global Animal Health Industry Dec 03 2014 
      Why Opko Health Is a Better Investment Than Apple Dec 02 2014 
      The Gurus’ Favorite Asian Stocks Sep 06 2014 
      George Soros Reveals His Largest Stake Jul 23 2014 
      George Soros Keeps Buying TEVA, EQT, YPF, EGN, CZR And Keeps Selling GOOGL, BA, MSFT, HAR Jul 16 2014 
      Diamond Hill Capital Comments on Teva Pharmaceutical Industries Ltd Jun 26 2014 
      Diamond Hill Select Fund Commentary – First Quarter 2014 Jun 25 2014 
      Top Guru Held Asian Companies of the First Quarter Jun 03 2014 
      George Soros Reports Top Five Stocks May 23 2014 

      More From Our Partners
      Teva's (TEVA) 2015 Guidance Hit By Generics - Analyst Blog Dec 12 2014 - ZACKS

      More From Other Websites
      Pfizer Ponies Up to Develop Long-acting Growth Hormone Dec 16 2014
      Teva's (TEVA) 2015 Guidance Hit By Generics Dec 12 2014
      Street Talk: Interesting Costco call Dec 12 2014
      Teva Upgraded On Strength Of Copaxone MS Drug Dec 12 2014
      UPDATE: Sterne Agee Upgrades Teva Pharmaceutical Dec 12 2014
      Teva Pharmaceutical TEVA) Stock Up Today on Higher 2015 Profit Estimate Dec 11 2014
      Teva Pharmaceutical Releases 2015 Guidance, Sees Increased Generic Competition Dec 11 2014
      Teva Pharm sees 2015 revenue lower than forecast Dec 11 2014
      Teva Pharm sees 2015 revenue lower than forecast Dec 11 2014
      Teva Provides 2015 Business Outlook Dec 11 2014
      Teva Provides Low-Key Revenue Outlook Dec 11 2014
      Teva Pharm sees lower than forecast 2015 revenue Dec 11 2014
      Teva Provides 2015 Business Outlook Dec 11 2014
      Teva Announces Launch of First Generic Celebrex® Capsules in the United States Dec 10 2014
      Teva Announces Launch of First Generic Celebrex® Capsules in the United States Dec 10 2014
      Merck-Cubist Deal Is On Despite Patent Setback Dec 09 2014
      Merck committed to Cubist after patent losses Dec 09 2014
      Merck committed to Cubist after patent losses Dec 09 2014
      Weekly 52-Week Highs Highlight: ITW, ESRX, TEVA, CHD, STI Dec 08 2014
      Teva Receives Positive Outcome in Europe for Three-Times-a-Week COPAXONE® (Glatiramer Acetate) 40... Dec 04 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK